Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965134 | 1.00 | KMT2A (0.55) | KMT2APOLBHTT | |
| SCHEMBL14965282 | 1.00 | KMT2A (0.55) | KMT2APOLBHTT | |
| SCHEMBL14965023 | 0.93 | KMT2A (0.49) | KMT2APOLBHTT | |
| SCHEMBL14965021 | 0.93 | KMT2A (0.49) | KMT2APOLBHTT | |
| SCHEMBL14965265 | 0.93 | KMT2A (0.49) | KMT2APOLBHTT | |
| SCHEMBL14965507 | 0.89 | POLB (0.54) | KMT2APOLBHTT | |
| SCHEMBL14965207 | 0.83 | KMT2A (0.57) | KMT2APOLBHTT | |
| SCHEMBL14965179 | 0.81 | KMT2A (0.57) | KMT2APOLBHTT | |
| SCHEMBL14964912 | 0.80 | KMT2A (0.54) | KMT2APOLBHTT | |
| SCHEMBL14964988 | 0.80 | KMT2A (0.54) | KMT2APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | KMT2A 1025/4885POLB 3644/4885HTT 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.